Key facts
- This page summarizes Ann E. Berman's Form 4 filing for Immuneering Corp (IMRX).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 02 Jan 2025, 16:19.
Ann E. Berman - 01 Jan 2025 Form 4 Insider Report for Immuneering Corp (IMRX)
- Reporting relationship
- Director
- Issuer ticker
- IMRX
- Reported as of
- 01 Jan 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 02 Jan 2025, 16:19:29 UTC
- Prior SEC filing
- 03 Dec 2024
- Next SEC filing
- 04 Mar 2025
- Source filing
- View source filing
- Reporting owner signature
- By: /s/ Michael D. Bookman, Attorney-in-Fact for Ann E. Berman
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Ann E. Berman filed Form 4 for Immuneering Corp (IMRX) on 02 Jan 2025.
Change
- Previous filing in this sequence was filed on 03 Dec 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
IMRX
transaction
Derivative
Stock Option
Award
- Transaction value
- $0
- Shares
- +23,485
- Change %
- Price
- $0.000000
- Shares after
- 23,485
- Date
- 01 Jan 2025
- Ownership
- Direct
- Underlying class
- Class A Common Stock
- Underlying amount
- 23,485
- Exercise price
- $2.20
- Footnotes
- F1, F2
IMRX
transaction
Derivative
Stock Option
Award
- Transaction value
- $0
- Shares
- +17,614
- Change %
- Price
- $0.000000
- Shares after
- 17,614
- Date
- 01 Jan 2025
- Ownership
- Direct
- Underlying class
- Class A Common Stock
- Underlying amount
- 17,614
- Exercise price
- $2.20
- Footnotes
- F3, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
Pursuant to the Immuneering Corporation Non-Employee Director Compensation Program (the "Compensation Program"), the reporting person elected to receive this stock option in lieu of receiving the cash Base Retainer (as defined in the Compensation Program).
Footnote F2
The option vests and becomes exercisable as to 25% of the shares subject to the option upon the reporting person completing three months of continuous service as a Non-Employee Director (as defined in the Compensation Program) following the grant date, such that the fourth and final installment will vest and become exercisable on the first anniversary of the grant date, subject in each case to such continuous service.
Footnote F3
Pursuant to the Compensation Program, the reporting person elected to receive this stock option in lieu of receiving the cash COB Retainer (as defined in the Compensation Program).
Footnote F4
The option vests and becomes exercisable as to 25% of the shares subject to the option upon the reporting person completing three months of continuous service as a Non-Employee Director (as defined in the Compensation Program) serving as Chair of the Board (as defined in the Compensation Program) following the grant date, such that the fourth and final installment will vest and become exercisable on the first anniversary of the grant date, subject in each case to such continuous service.